In the Trial of Atorvastatin in Rheumatoid Arthritis (TARA), atorvastatin 40 mg daily, as an adjunct to disease‐modifying antirheumatic drug (DMARD) therapy, provided a modest additional benefit for control of inflammation in RA, at least in a subgroup of patients 16, while the Tayside controlled study of rosuvastatin in RA suggested a potentially beneficial effect on C‐reactive protein (CRP) levels 17. The gene discussed is CRP; the disease is rheumatoid arthritis.